prof. dr. H.W. Frijlink
Curriculum vitae: Henderik W. Frijlink
Department of Pharmaceutical Technology and Biopharmacy,
University of Groningen, The Netherlands.
Dr. Frijlink received his pharmaceutical training at the University of Groningen (The Netherlands), where he received his Ph.D. degree in Pharmaceutical Technology. He served for two years as a pharmacist in the Martini Hospital (Groningen, Nl). From 1992 to 1997 he was head of the Pharmaceutical Development Department of Solvay Pharmaceuticals. Since 1998 Dr. Frijlink is Professor and Chairman of the Department of Pharmaceutical Technology and Biopharmacy at the Groningen University Institute for Drug Exploration. The main interests of his current research are technical and biopharmaceutical aspects of pulmonary drug delivery and the development of dry powder inhalers. The formulation of biopharmaceuticals such as peptides, proteins, vaccines and gene based products using stabilizing sugar glasses is a further research topic in his department. He is interested in solid oral dosage forms, their technological and biopharmaceutical aspects and gastro-intestinal targeting strategies. Finally, he is interested in development, scale up and quality aspects of pharmaceutical production.
Since 2016 Dr. Frijlink is Director of the Groningen Research Institute of Pharmacy
Pharm.D., Registered Teaching Pharmacist
Publications and patents
(Co-) author of 250 original articles in peer reviewed journals in the field of pharmaceutical technology.
Dr. Frijlink is named as (co-)inventor in 20 patents in the field of pharmaceutical dosage forms and production processes.
Frijlink was project leader and/or participant in three Dutch Top Institute Pharma projects. He was the Principal Coordinating Investigator in the UniSec project. UniSec is a European consortium consisting of 3 academic partners, 5 National Health Institutes and 3 SMEs, devoted to the development of universal influenza vaccines. The project was funded from the 7th framework programme (HEALTH 2013.2.3.0-1) and was carried out between 2013 and 2018. Furthermore, Frijlink is participant in the “iABC” project, an EU Innovative Medicines Initiative (IMI) project, which is devoted to the development of inhalable antibiotics for patients with cystic fibrosis and bronchiectasis and he is participant in the “Novel virucidal drugs” project a Swiss synergy fund granted project.
Astellas Basic Science Award 2008-2009
Wubbo Ockels Award 2010
Utrecht University Award for Excellence in Pharmaceutical Research 2015
Grants, research support and royalties
In total (2000-2019): 36,3 Million €
Pharmaceutical Degree, University of Groningen (NL), 1985
Registered Pharmacist, University of Groningen (NL) 1990
Ph.D. Pharmaceutical Technology, University of Groningen (NL) 1990
1983-1985: Teaching assistant University of Groningen (NL)
1986-1990: Ph. D. student University of Groningen (NL)
1990: Post-doc researcher University of Groningen (NL)
1990-1992: Pharmacist, Martini Hospital Groningen (NL)
1992-1997: Head, Dosage Form Development Department EU, Solvay Pharmaceuticals
1998-present: Chairman of the Department of Pharmaceutical Technology and Biopharmacy, University of Groningen (NL)
2016-present: Director of the Groningen Research Institute of Pharmacy, University of Groningen (NL)
PhD theses (co-)supervised
Up to 2019 Frijlink supervised 41 PhD projects
|Last modified:||25 May 2021 9.34 p.m.|